Predictive value of early PSMA upregulation for the response to enzalutamide ± (177)Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.

Emmett L, Swiha M, Papa N, Subramaniam S, Crumbaker M, Joshua AM, Nguyen A, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Pathmanandavel S, Hope T, Ayati N, Hofman MS, Sandhu S, Niu C, Martin AJ, Thomas H, Stockler MR, Davis ID, Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group

Open source

DOI: 10.1038/s43018-026-01140-3
Published: 2026 Apr
Container: Nature cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s43018-026-01140-3,
  title = {Predictive value of early PSMA upregulation for the response to enzalutamide ± (177)Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.},
  author = {Emmett L and Swiha M and Papa N and Subramaniam S and Crumbaker M and Joshua AM and Nguyen A and Weickhardt A and Lee ST and Ng S and Francis RJ and Goh JC and Pattison DA and Pathmanandavel S and Hope T and Ayati N and Hofman MS and Sandhu S and Niu C and Martin AJ and Thomas H and Stockler MR and Davis ID and Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group},
  year = {2026},
  journal = {Nature cancer},
  doi = {10.1038/s43018-026-01140-3},
  url = {https://doi.org/10.1038/s43018-026-01140-3}
}

RIS

TY  - JOUR
TI  - Predictive value of early PSMA upregulation for the response to enzalutamide ± (177)Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.
AU  - Emmett L
AU  - Swiha M
AU  - Papa N
AU  - Subramaniam S
AU  - Crumbaker M
AU  - Joshua AM
AU  - Nguyen A
AU  - Weickhardt A
AU  - Lee ST
AU  - Ng S
AU  - Francis RJ
AU  - Goh JC
AU  - Pattison DA
AU  - Pathmanandavel S
AU  - Hope T
AU  - Ayati N
AU  - Hofman MS
AU  - Sandhu S
AU  - Niu C
AU  - Martin AJ
AU  - Thomas H
AU  - Stockler MR
AU  - Davis ID
AU  - Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group
PY  - 2026
JO  - Nature cancer
DO  - 10.1038/s43018-026-01140-3
UR  - https://doi.org/10.1038/s43018-026-01140-3
ER  -

APA

L, E., M, S., N, P., S, S., M, C., AM, J., A, N., A, W., ST, L., S, N., RJ, F., JC, G., DA, P., S, P., T, H., N, A., MS, H., S, S., C, N., AJ, M., H, T., MR, S., ID, D., & Group, A. A. N. Z. U. A. P. (. C. T. (2026). Predictive value of early PSMA upregulation for the response to enzalutamide ± (177)Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.. Nature cancer. https://doi.org/10.1038/s43018-026-01140-3

Source records

pubmed · retrieved 2026-09-26T22:11:56.510Z